EyeArt® News

Eyenuk’s AI Eye Screening System for Diabetic Retinopathy Demonstrates Exceptional Performance in a Prospective, Multi-Center, Pivotal Clinical Trial

LOS ANGELES, Calif., April 28, 2019 – Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today results from its landmark prospective, multi-center, pivotal clinical trial to validate the EyeArt® AI Eye Screening System for autonomous detection of diabetic retinopathy (DR),

Eyenuk To Provide Artificial Intelligence (AI) Eye Screening to Thousands of Italians Through Collaboration With Ambrosian Ophthalmic Center in February

– 30 Centers Across Italy Will Provide AI Eye Screening for Diabetic Retinopathy, the Leading Cause of Vision Loss Among Working-age Adults – LOS ANGELES–Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today that it is providing EyeArt® AI Eye

Eyenuk, Inc. presents EyeArt™ 2.0 at EASDec 2016 in Manchester

Eyenuk, Inc. will be attending the twenty-sixth EASDec 2016 conference in Manchester, UK from June 23rd to June 25th. Along with hosting a booth, Eyenuk CEO, Kaushal Solanki, will be presenting Eyenuk’s EyeArt™ 2.0 technology during Session 5 of the conference: “Imaging and New Technologies” on Saturday June 25 at 9:00am GMT. EASDec is a study group of the